Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
varicella-zoster virus vaccine (HIV-NAT)
- Development stage
- Approved
- Lead developer
- Merck
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
The varicella-zoster virus (VZV) vaccine is a live-attenuated viral vaccine designed to provide active immunity against chickenpox (varicella) and reduce the risk of herpes zoster (shingles). Most formulations utilize the Oka strain of VZV, which is attenuated through serial passage in cell culture. The vaccine stimulates both humoral (antibody) and cell-mediated immune responses. In the specific context of research conducted by The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), this vaccine has been evaluated in Phase 4 clinical trials to assess its safety, immunogenicity, and efficacy in HIV-infected children who are on stable antiretroviral therapy. This research is particularly significant as immunocompromised populations are at an increased risk for severe complications from primary VZV infection and viral reactivation.
- Brand names
- VarivaxVarilrixOkavax
- Other names
- Chickenpox vaccineLive-attenuated varicella-zoster virus vaccine
Beyond the preview
Go deeper on varicella-zoster virus vaccine (HIV-NAT).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on varicella-zoster virus vaccine (HIV-NAT).